REGN
Regeneron Pharmaceuticals, Inc. · Healthcare · Biotechnology
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q2 2024
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | -1 | 74.11K | $47.57M | n/a | −4 |
| Q2 2026 | 167 | -1 | 75.04M | $46.86B | +5 | −7 |
| Q1 2026 | 172 | -4 | 77.87M | $60.04B | +2 | −7 |
| Q4 2025 | 175 | 0 | 81.03M | $62.54B | +1 | n/a |
| Q3 2025 | 27 | -1 | 48.96M | $27.52B | n/a | −2 |
| Q2 2025 | 26 | +2 | 40.24M | $21.12B | +3 | −1 |
| Q1 2025 | 21 | +1 | 16.62M | $10.53B | +1 | n/a |
| Q4 2024 | 20 | -1 | 17.24M | $12.28B | n/a | −1 |
| Q3 2024 | 20 | +1 | 13.10M | $13.76B | +2 | −1 |
| Q2 2024 | 19 | n/a | 13.77M | $14.47B | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 4.64M | n/a | $4.88B | 0.8% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (pasivo) | 2.42M | n/a | $2.53B | 0.2% | n/c | 1 | SEC ↗ ×2 |
| 3 | Dodge & Cox ✦ | 2.32M | n/a | $2.43B | 1.5% | n/c | 1 | SEC ↗ |
| 4 | Norges Bank ✦ (pasivo) | 1.13M | n/a | $1.18B | 0.2% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 1.06M | n/a | $1.12B | 0.2% | n/c | 1 | SEC ↗ ×8 |
| 6 | T. Rowe Price ✦ | 932.87K | n/a | $980.48M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 7 | Millennium Management ✦ | 267.03K | n/a | $280.66M | 0.2% | n/c | 1 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 254.41K | n/a | $267.40M | 0.4% | n/c | 1 | SEC ↗ ×2 |
| 9 | AQR Capital Management ✦ | 189.29K | n/a | $198.57M | 0.3% | n/c | 1 | SEC ↗ ×3 |
| 10 | Renaissance Technologies ✦ | 185.16K | n/a | $194.61M | 0.3% | n/c | 1 | SEC ↗ |
| 11 | Adage Capital Partners ✦ | 162.50K | n/a | $170.79M | 0.3% | n/c | 1 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 109.56K | n/a | $115.15M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | Marshall Wace ✦ | 58.87K | n/a | $61.88M | 0.1% | n/c | 1 | SEC ↗ |
| 14 | Point72 Asset Management ✦ | 22.87K | n/a | $24.04M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | ARK Investment Management ✦ | 15.87K | n/a | $16.67M | 0.1% | n/c | 1 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 5.70K | n/a | $5.99M | 0.1% | n/c | 1 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 5.67K | n/a | $5.95M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Bridgewater Associates ✦ | 5.35K | n/a | $5.63M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | GAMCO Investors ✦ | 307 | n/a | $322,666 | 0.0% | n/c | 1 | SEC ↗ |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Sin nuevos compradores rastreados este trimestre. |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 1,385 tenedores, 83.52M acciones, $61.43B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer · 50 acc. · $39,074
Officer · 127 acc. · $97,701
Officer · 12 acc. · $9,242
Officer · 283 acc. · $218,351
Officer · 211 acc. · $163,010
Officer · 224 acc. · $173,242
Officer · 121 acc. · $93,712
Officer · 376 acc. · $291,573
Officer · 66 acc. · $51,236
Officer · 38 acc. · $29,555
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología